

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Gaush Meditech Ltd

高視医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2407)

VOLUNTARY ANNOUNCEMENT GAUSH TECH OBTAINS INTERNATIONAL QUALITY MANAGEMENT SYSTEM CERTIFICATION FOR MEDICAL DEVICES

This announcement is made by Gaush Meditech Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis, to inform the shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that Gaush Tech Ltd.* (深圳高視科技有限公司) (“**Gaush Tech**”), a subsidiary of the Company, has recently been officially awarded the ISO 13485: 2016/EN ISO 13485: 2016 Quality Management System Certification for Medical Devices (Certificate No.: 4932952) by DEKRA. This certification comprehensively covers the entire process of design, development, production and sale of ophthalmic electrophysiology equipment, corneal contact lens, and fluid collection cassettes for phacoemulsification and vitrectomy surgery system.

DEKRA, founded in 1925, is the world’s leading independent, non-listed expert organization in the field of testing, inspection and certification, serving a wide range of industries.

ISO 13485 is a specialized quality management system standard for the medical device industry, issued by the International Organization for Standardization (“**ISO**”). It focuses on “patient-centric” risk management and full-process quality control, serving as a core compliance benchmark recognized by global medical device regulatory authorities, such as China’s NMPA, EU CE and U.S. FDA. Achieving this certification signifies that an enterprise has established a robust quality management system spanning the entire product lifecycle, including design and development, production, inspection and after-sales service, ensuring compliance with regulatory requirements and a commitment to continuous improvement.

The attainment of this prestigious certification represents another significant achievement of the Company in the establishment of its quality management system, laying a solid foundation for the Company to expand into international markets on an ongoing basis.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board

Gaush Meditech Ltd

Mr. Gao Tieta

Chairman and Executive Director

Hong Kong, December 1, 2025

As of the date of this announcement, the Board comprises Mr. Gao Tieta as Chairman and executive Director, Mr. Liu Xinwei, Mr. Zhao Xinli, Mr. Zhang Jianjun and Ms. Li Wenqi as executive Directors, Dr. David Guowei Wang as non-executive Director, and Mr. Feng Xin, Mr. Wang Li-Shin and Mr. Chan Fan Shing as independent non-executive Directors.

* *For identification purpose only*